| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Based on the clinical observation that a part of patients with systemic sclerosis (SSc) develops skin sclerosis due to Koebner phenomenon, we investigated molecules invovled in this phenomenon and sought to develop a new treatment targeting such molecules against skin sclerosis of SSc. We identified IL-1 alpha and CTGF that are invovled in the epithelial cell-dependent induction of skin fibrosis in epithelial cell-specific Fli1 knockout mice (Fli1 flox/flox; K14-Cre) which spontaneously develop skin fibrosis. We also found the potential of epithelial cell-producing psoriasin and LL-37 to promote the development of skin fibrosis in the clinical studies with sera and skin sections of SSc patients. We are currently going to generate oligonucleotide therapeutics targeting these molecules produced by epithelial cells by using drug delivery system such as ointment, cream and microneedle.
|
